The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer

Reed, Melissa; Patrick, Caitlyn; Croft, Brianna; Walde, Natalie; Voutsadakis, Ioannis A.

doi:10.1007/s12664-018-0923-0

Cited by 7 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding duplicates, 1,108 underwent title and abstract screening (Figure 1). A total of 55 articles were assessed in full text and, of these, 17 original articles met our inclusion criteria [36–52], four of which reported on two studies [48, 49, 51, 52]. Restricting consideration to articles reporting more up‐to‐date data [52] or more informative analyses [48], this resulted in 15 eligible studies and articles.…”

Section: Resultsmentioning

confidence: 99%

“…Restricting consideration to articles reporting more up‐to‐date data [52] or more informative analyses [48], this resulted in 15 eligible studies and articles. [36–48, 50, 52].…”

Section: Resultsmentioning

confidence: 99%

“…The 15 eligible studies were published between 2009–2019 (Table 2) [36–48, 50, 52]. All had a cohort design.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and meta‐analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes

Koo

McPherson

et al. 2022

Colorectal Disease

View full text Add to dashboard Cite

Aim Metabolic syndrome (MetS) is a cluster of factors including obesity, hypertension, diabetes, hypercholesterolemia and hyperlipidaemia. It has been associated with an increased risk of colorectal neoplasia. This systematic review and meta‐analysis assessed the association between MetS and (i) recurrence of adenomas or occurrence of CRC in patients with prior adenomas, and (ii) survival in patients with CRC. Method MEDLINE, Embase, Scopus and Web of Science were searched up to 22 November 2019. Two authors independently conducted title and abstract screening; full text of eligible studies was evaluated. Where ≥3 studies reported effect measures for a specific outcome, meta‐analysis using random effects model was conducted. I2 was used to assess between‐study heterogeneity. Quality appraisal was undertaken with the Newcastle‐Ottawa Score. Results The search identified 1,764 articles, 55 underwent full text screening, resulting in a total of 15 eligible studies. Five studies reported on metachronous neoplasia, with differing outcomes precluded a meta‐analysis. No consistent relationship between MetS and metachronous neoplasia was found. Ten studies reported on survival outcomes. MetS was associated with poorer CRC‐specific survival (HR = 1.8, 95% CI: 1.04–3.12, I2 = 92.7%, n = 3). Progression‐free survival was also worse but this did not reach statistical significance (HR = 1.12, 95% CI: 0.89–1.42, I2 = 85.6%, n = 3). There was no association with overall survival (HR = 1.04, 95% CI: 0.94–1.15, I2 = 43.7%, n = 7). Significant heterogeneity was present but subgroup analysis did not account for this. Conclusion MetS is associated with poorer CRC‐specific survival, but evidence is inconsistent on metachronous neoplasia. Further research is warranted to better understand the impact of MetS on the adenoma‐carcinoma pathway.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Restricting consideration to articles reporting more up‐to‐date data [52] or more informative analyses [48], this resulted in 15 eligible studies and articles. [36–48, 50, 52].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and meta‐analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes

Koo

McPherson

et al. 2022

Colorectal Disease

View full text Add to dashboard Cite

show abstract

“…Nozawa et al [34] demonstrated that patients with metastatic CRC who underwent successful conversion to resection after chemotherapy had similar outcomes as patients with initially resectable stage IV CRC. Reed et al [35] reported that diabetes or other metabolic syndrome elements were not prognostic factors for progression-free survival and OS in metastatic CRC. In our study, no difference was observed in long-term survival between the MET < 12 group and the MET ≥ 12 group.…”

Section: Discussionmentioning

confidence: 99%

Association of Preoperative Physical Activity with Short- and Long-Term Outcomes in Patients Undergoing Palliative Resection for Metastatic Colorectal Cancer: An Inverse Probability of Treatment Weighting Analysis

Cheng

Lai

Tsai

et al. 2022

Cancers

View full text Add to dashboard Cite

A lack of physical activity is a generally accepted risk factor for colorectal cancer. However, research on the effect of preoperative physical activity on postoperative and long-term outcomes is limited, especially in patients with stage IV colorectal cancer who underwent palliative surgery. Patients who underwent bowel resection for stage IV primary colorectal cancer between January 1995 and December 2016 were retrospectively enrolled. A total of 2185 patients were divided into two groups according to preoperative leisure-time weekly physical activity as assessed by metabolic equivalent of task (MET) values: MET < 12 (n = 1845) and MET ≥ 12 (n = 340). Inverse probability of treatment weighting (IPTW) was used to reduce imbalance and selection biases between the two groups. After the IPTW process, the MET < 12 group showed a higher postoperative morbidity rate (18.7% vs. 10.6%; p < 0.001) and mortality rate (2.4% vs. 0.6%; p < 0.001) than the MET ≥ 12 group. No significant difference was found in overall survival. Weekly preoperative leisure-time physical activity with MET ≥ 12 was associated with reduced short-term postoperative morbidity and mortality in patients undergoing palliative resection for metastatic colorectal cancer. However, no difference was detected in long-term survival.

show abstract

“…The first is from Menon and Matthew [1], who reported that elements of metabolic syndrome were independent risk factors for the development of hepatobiliary cancer, through a large study on 4297 patients with hepatobiliary cancers and 8574 age-and gendermatched controls. The second is from the group of Reed et al [2], who reported a retrospective cohort of 123 patients with metastatic colorectal cancer, highlighting that patients with diabetes mellitus had shorter progression-free survival.…”

mentioning

confidence: 99%

Metabolic syndrome and gastrointestinal cancers

Lee¹,

Koh²,

Ho³

2019

Indian J Gastroenterol

View full text Add to dashboard Cite

The metabolic syndrome and its components as prognostic factors in metastatic colorectal cancer

Cited by 7 publications

References 19 publications

Systematic review and meta‐analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes

Systematic review and meta‐analysis: Associations between metabolic syndrome and colorectal neoplasia outcomes

Association of Preoperative Physical Activity with Short- and Long-Term Outcomes in Patients Undergoing Palliative Resection for Metastatic Colorectal Cancer: An Inverse Probability of Treatment Weighting Analysis

Metabolic syndrome and gastrointestinal cancers

Contact Info

Product

Resources

About